6P - Predictors of Metastatic Contralateral Spread of Breast Cancer

Date 04 May 2017
Event IMPAKT 2017
Session Welcome reception and Poster Walk
Topics Breast Cancer
Imaging, Diagnosis and Staging
Presenter Mohamed Hendawi
Authors M. Hendawi
  • Department Of Urology, The Ohio state University, 43212 - columbus/US

Abstract

Body

Introduction and Objectives:
Contralateral breast cancer is either a metastatic lesion or the second primary cancer.The understanding of metastatic patterns for contralateral breast cancer (CBC) may help determine the biological nature of CBC.Our study aim is to identify possible predictors for metastatic (CBC).
Method’s

The records of all patients with metastatic breast cancer were extracted from SEER database (The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute). Data were extracted to SPSS 22 statistics. Univariate and multivariate analysis were used to identify clinical predictors of metastatic contralateral breast cancer spread.
Results
We have identified 22095 patients with metastatic breast cancer (2004-2013). We excluded patients who were men. Only patients who had one primary cancer were included in the analysis. The Majority of patients were of white race (77%). Primary tumor location was more frequently in the left ( 49%) breast than the right breast (46%), and bilateral in 4.8% of cases .
Our multivariate analysis showed that High grade tumors (p<0.001, 95% CI: 1.8-6.6), Lobular and adenocarcinoma histology (p<0.001, 95%CI: 1.8- 10) were independent risk factors for contralateral spread of breast cancer. Patients who received radiation therapy had lower rates of contralateral spread of cancer (OR: 0.23, p=0.01, 95%:0.073-0.76). Estrogen and progesterone status was not a factor in regard of contralateral spread.

Conclusion :
High grade lobular and adenocarcinoma have high rates of contralateral breast spread. Patients who received radiation therapy had significantly lower rates of contralateral spread. Prophylactic radiation therapy should be encouraged for al high risk groups. Further investigation needed to identify the biology of those patterns.

Clinical trial identification